Condition: Heterozygous Familial Hypercholesterolemia · Premature Coronary Heart Disease · Sponsor: Verve Therapeutics, Inc.
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Clinical Study Center | Dothan, Alabama, United States | Recruiting |
| Clinical Study Center | Pomona, California, United States | Recruiting |
| Clinical Study Center | Boca Raton, Florida, United States | Recruiting |
| Clinical Study Center | Jacksonville, Florida, United States | Recruiting |
| Clinical Study Center | Winter Park, Florida, United States | Recruiting |
| Clinical Study Center | High Point, North Carolina, United States | Recruiting |
| Clinical Study Center | DeSoto, Texas, United States | Recruiting |
| Clinical Study Center | Renton, Washington, United States | Recruiting |
| Clinical Study Center | Adelaide, Australia | Recruiting |
| Clinical Study Center | Melbourne, Australia | Recruiting |
| Clinical Study Center | Sydney, Australia | Recruiting |
| Clinical Study Center | Chicoutimi, Canada | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06164730